Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

In various embodiments, the present disclosure provides methods of diagnosing a need for peripheral arterial revascularization and/or reducing a need for peripheral arterial revascularization in a subject by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

In various embodiments, the present disclosure provides methods of diagnosing a need for peripheral arterial revascularization and/or reducing a need for peripheral arterial revascularization in a subject by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value.

A composition is provided comprising an effective amount of a combination of gamma linolenic acid (GLA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). The composition comprises about 5% w/w to about 25% w/w GLA, and about 5% w/w to about 25% w/w of a mixture of DHA and EPA. Methods of modulating fatty acid profiles or treating an inflammatory condition in a horse include administering an effective amount of the composition to the horse. The inflammatory conditions capable of being treated include gastric ulcers, airway inflammation, joint inflammation, or combinations thereof.

A composition is provided comprising an effective amount of a combination of gamma linolenic acid (GLA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). The composition comprises about 5% w/w to about 25% w/w GLA, and about 5% w/w to about 25% w/w of a mixture of DHA and EPA. Methods of modulating fatty acid profiles or treating an inflammatory condition in a horse include administering an effective amount of the composition to the horse. The inflammatory conditions capable of being treated include gastric ulcers, airway inflammation, joint inflammation, or combinations thereof.